The DOI matches its Crossref record; 409 of the 409 references it cites were found in a registry or an index.
Raf Family Kinases: Old Dogs Have Learned New Tricks
Open accessAbstract
First identified in the early 1980s as retroviral oncogenes, the Raf proteins have been the objects of intense research. The discoveries 10 years later that the Raf family members (Raf-1, B-Raf, and A-Raf) are bona fide Ras effectors and upstream activators of the ubiquitous ERK pathway increased the interest in these proteins primarily because of the central role that this cascade plays in cancer development. The important role of Raf in cancer was corroborated in 2002 with the discovery of B-Raf genetic mutations in a large number of tumors. This led to intensified drug development efforts to target Raf signaling in cancer. This work yielded not only recent clinical successes but also surprising insights into the regulation of Raf proteins by homodimerization and heterodimerization. Surprising insights also came from the hunt for new Raf targets. Although MEK remains the only widely accepted Raf substrate, new kinase-independent roles for Raf proteins have emerged. These include the regulation of apoptosis by suppressing the activity of the proapoptotic kinases, ASK1 and MST2, and the regulation of cell motility and differentiation by controlling the activity of Rok-α. In this review, we discuss the regulation of Raf proteins and their role in cancer, with special focus on the interacting proteins that modulate Raf signaling. We also describe the new pathways controlled by Raf proteins and summarize the successes and failures in the development of efficient anticancer therapies targeting Raf. Finally, we also argue for the necessity of more systemic approaches to obtain a better understanding of how the Ras-Raf signaling network generates biological specificity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 401–409 of 409
Roignant, J., Hamel, S., Janody, F., & Treisman, J. E. (2006) · Genes & Development · doi:10.1101/gad.1390506 · Cited by 25
Chakraborty, A. K., Das, J., Zikherman, J., Yang, M., Govern, C. C., Ho, M., Weiss, A., & Roose, J. P. (2009) · Science Signaling · doi:10.1126/scisignal.266pt2 · Cited by 24
Disrupting the Rb-Raf-1 Interaction: A Potential Therapeutic Target for Cancer
Davis, R. K., & Chellappan, S. (2008) · Drug News & Perspectives · doi:10.1358/dnp.2008.21.6.1246832 · Cited by 22
A-RAF Kinase Functions in ARF6 Regulated Endocytic Membrane Traffic
Nekhoroshkova, E., Albert, Š., Becker, M., & Rapp, U. R. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004647 · Cited by 22
Signaling Threshold Regulation by the Ras Effector IMP
Matheny, S. A., & White, M. A. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.r800082200 · Cited by 21
Raf-1: a novel cardiac troponin T kinase
Pfleiderer, P. J., Sumandea, M. P., Rybin, V. O., Wang, C., & Steinberg, S. F. (2009) · Journal of Muscle Research and Cell Motility · doi:10.1007/s10974-009-9176-y · Cited by 19
Raf-1 and B-Raf promote protein kinase C θ interaction with BAD
Hindley, A. D., & Kölch, W. (2006) · Cellular Signalling · doi:10.1016/j.cellsig.2006.08.004 · Cited by 19
Non-Hodgkin Lymphoma in a Patient With Cardiofaciocutaneous Syndrome
Ohtake, A., Aoki, Y., Saito, Y., Niihori, T., Shibuya, A., Kure, S., & Matsubara, Y. (2010) · Journal of Pediatric Hematology/Oncology · doi:10.1097/mph.0b013e3181df5e5b · Cited by 18
Chakraborty, A. K., Das, J., Zikherman, J., Yang, M., Govern, C. C., Ho, M., Weiss, A., & Roose, J. P. (2009) · PubMed Central · Cited by 11
Cited by
Targeting RAS–ERK signalling in cancer: promises and challenges
Samatar, A. A., & Poulikakos, P. I. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4281 · Cited by 1,163
A Comprehensive Review on MAPK: A Promising Therapeutic Target in Cancer
Braicu, C., Buse, M., Busuioc, C., Drula, R., Gulei, D., Raduly, L., Rusu, A., Irimie, A., Atanasov, A. G., Slaby, O., et al. (2019) · Cancers · doi:10.3390/cancers11101618 · Cited by 944
Targeting the RAS/RAF/MAPK pathway for cancer therapy: from mechanism to clinical studies
Bahar, M. E., Kim, H. J., & Kim, D. R. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01705-z · Cited by 888
Targeting MAPK Signaling in Cancer: Mechanisms of Drug Resistance and Sensitivity
Lee, S., Rauch, J., & Kolch, W. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21031102 · Cited by 799
Self-citationRegulation of RAF protein kinases in ERK signalling
Lavoie, H., & Therrien, M. (2015) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3979 · Cited by 702
Metadata
- Authors
- Matallanas, D., Birtwistle, M., Romano, D., Zebisch, A., Rauch, J., von Kriegsheim, A., & Kolch, W.
- Venue
- Genes & Cancer
- Publisher
- SAGE Publications
- Published
- 2011-03-01
- Volume
- 2
- Issue
- 3
- Pages
- 232-260
- ISSN
- 1947-6019 (ISSN-L)
- 1947-6027
- OpenAlex
- W2000581759
- Cited by
- 386
- References
- 409
- FWCI
- 8.82
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.